OliX Pharmaceuticals, Inc (KOSDAQ:226950)
South Korea flag South Korea · Delayed Price · Currency is KRW
111,600
-2,600 (-2.28%)
Sep 18, 2026, 3:30 PM KST

OliX Pharmaceuticals Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
111,4826,3593,88311,9834,93034,337
Short-Term Investments
79,10691,900-10,00053,00015,000
Trading Asset Securities
23,56134,2558,5313,9423,941420.68
Cash & Short-Term Investments
214,149132,51312,41425,92561,87249,757
Cash Growth
2642.15%967.42%-52.11%-58.10%24.35%-26.95%
Accounts Receivable
-5,12795.113,55853.23-
Other Receivables
2,3971,115907.841,419996.88272.13
Receivables
2,5256,2421,0034,9771,050491.49
Inventory
426.18396.71554.26468.41657.17374.13
Prepaid Expenses
2,3491,5661,370244.91,3671,480
Other Current Assets
130.15134.21192.88526.8699136.92
Total Current Assets
219,578140,85115,53432,14265,04652,240
Property, Plant & Equipment
50,57150,49951,38543,91037,23231,525
Long-Term Investments
1,4261,3521,98623,48126,8090.5
Other Intangible Assets
1,9901,9441,7051,9812,1072,134
Other Long-Term Assets
500.48719.66639.621,3121,458772.05
Total Assets
274,065195,36671,249102,825132,65186,672

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accrued Expenses
406.79738.78488.52465.36358.62297.85
Short-Term Debt
-64413,441---
Current Portion of Long-Term Debt
3,5713,5713,572-19,23016,405
Current Portion of Leases
441.19318.3745.851,065939.87487.8
Current Income Taxes Payable
-2.8153.77---
Other Current Liabilities
14,28816,05111,7595,03319,01423,174
Total Current Liabilities
18,70821,32630,0606,56339,54340,365
Long-Term Debt
16,07117,85721,42835,36220,00020,326
Long-Term Leases
735.26895.925.382,9303,82651.69
Pension & Post-Retirement Benefits
157.05-414.47--225.41
Other Long-Term Liabilities
973.795,208867.987,6343,0806,296
Total Liabilities
36,64545,28752,77752,48966,44967,265

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
10,49610,0959,2308,0106,8526,852
Additional Paid-In Capital
428,360323,423175,533157,177151,89592,908
Retained Earnings
-212,381-191,586-167,785-122,910-103,224-84,303
Comprehensive Income & Other
9,2146,458871.877,1418,8853,064
Total Common Equity
235,689148,39017,84949,41864,40718,521
Minority Interest
741.41699.37623.76481.45295.16886.27
Shareholders' Equity
237,420150,07918,47350,33666,20319,407
Total Liabilities & Equity
274,065195,36671,249102,825132,65186,672

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
20,81923,28739,19239,35743,99637,271
Net Cash (Debt)
193,329109,227-26,778-13,43317,87612,487
Net Cash Growth
----43.16%-76.70%
Net Cash Per Share
9132.855553.79-1589.86-930.931304.50912.36
Filing Date Shares Outstanding
20.9920.1918.4616.0213.713.7
Total Common Shares Outstanding
20.9920.1918.4616.0213.713.7
Working Capital
200,871119,525-14,52625,57825,50211,874
Book Value Per Share
11227.317349.70966.923084.794700.191351.59
Tangible Book Value
233,700146,44516,14447,43762,30016,387
Tangible Book Value Per Share
11132.547253.40874.552961.164546.391195.84
Land
25,32525,32525,46025,74025,74025,740
Buildings
22,89622,69023,0333,3543,3543,354
Machinery
8,2497,6597,4256,4365,5184,427
Construction In Progress
245.86169.57-8,9481,23971.73